Product
LYL797
1 clinical trial
11 indications
Indication
Triple-Negative Breast CancerIndication
Lung CancerIndication
Non Small Cell Lung Cancer MetastaticIndication
TNM Stage 4Indication
Breast CancerIndication
NSCLCIndication
RecurrentIndication
Non-Small Cell Lung Cancer Stage IVIndication
Relapsed CancerIndication
Relapse/RecurrenceIndication
Recurrent non-small cell lung cancerClinical trial
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-01